The efficacy and safety of intravitreal dexamethasone implants for macular oedema secondary to retinal vein occlusion: 3‐year experience

Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1‐year results of the COMRADE extension study

“…These findings are in line with the known safety profile of DEX implants, as reported in the summary of product characteristics (SmPC) (EMA 2010) and in other trials and case reports (Haller et al 2010(Haller et al , 2011Higham et al 2016). Incidence rates of ocular TEAEs in the study eye were higher with DEX than ranibizumab in BRVO patients (62.5% versus 55.8%) and vice versa in CRVO patients (59.1% versus 65.6%).…”

“…Treatment-emergent adverse events (TEAEs) occurring more often with DEX than ranibizumab included increased IOP in both indications, conjunctival haemorrhage and cataract formation in BRVO patients. These findings are in line with the known safety profile of DEX implants, as reported in the summary of product characteristics (SmPC) (EMA 2010) and in other trials and case reports (Haller et al 2010(Haller et al , 2011Higham et al 2016). Treatment-emergent adverse event (TEAEs) that were reported more frequently for ranibizumab included relapse of macular oedema in both indications, eye pain in BRVO patients, and reduced VA in CRVO patients.…”

Head‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B)

“…; Higham et al. ), with Gado et al. suggesting a retreatment with dexamethasone at approximately 4 months after the initial first treatment (Gado & Macky ).…”

“…The dexamethasone intravitreal implant, a potent, water‐soluble, biodegradable corticosteroid that is delivered into the vitreous cavity, provides an alternative method of treating macular oedema secondary to BRVO (Higham et al. ). Dexamethasone intravitreal implant was approved in June 2009 by the US FDA for the treatment of macular oedema secondary to BRVO based on the 6‐month results of a phase III sham‐controlled study ‘Global Evaluation of implaNtable dExamethasone in retinal Vein occlusion with macular edemA’ (GENEVA) (Haller et al.…”

Effect of intravitreal dexamethasone implant on intra‐ocular cytokines and chemokines in eyes with retinal vein occlusion

“…; Higham et al. ). In the phase III GENEVA study, a significant best‐corrected visual acuity (BCVA) improvement could be shown in 1267 patients after dexamethasone treatment with the greatest effect observed 60 days after application (Haller et al.…”